PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic Journal

Neuroscience Bulletin

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

Neuroscience Bulletin has 1 tracked paper indexed in Blossom (2016) from 6 authors, most often covering Ketamine, across Major Depressive Disorder (MDD), Depressive Disorders and Suicidality.

Published Papers

Paywallmeta

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant

This review (2016) investigates the risks (safety and toxicity) related to the medical use of ketamine (for depression). The most risk is found at chronic and high doses. arketamine is found to have greater antidepressant effects with a smaller risk of adverse events.

Published
November 22, 2016
Journal
Neuroscience Bulletin
Authors
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., Lu, L.

Quick Facts

Papers Indexed
1
h-Index
71
Open Access
No
Publisher
Springer Nature
Country
China
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.